Genetic Technologies (NASDAQ:GENE) Trading Up 5.4%

Genetic Technologies Limited (NASDAQ:GENE) shares were up 5.4% on Friday . The stock traded as high as $0.62 and last traded at $0.59, approximately 135,387 shares were traded during mid-day trading. A decline of 72% from the average daily volume of 480,932 shares. The stock had previously closed at $0.56.

Separately, ValuEngine cut shares of Genetic Technologies from a “buy” rating to a “hold” rating in a research note on Monday, May 13th.

The company’s 50 day simple moving average is $0.63.

A hedge fund recently bought a new stake in Genetic Technologies stock. Alpine Group USVI LLC acquired a new stake in shares of Genetic Technologies Limited (NASDAQ:GENE) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 28,437 shares of the biotechnology company’s stock, valued at approximately $25,000. Genetic Technologies accounts for approximately 0.1% of Alpine Group USVI LLC’s holdings, making the stock its 15th largest holding. Alpine Group USVI LLC owned 0.18% of Genetic Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 3.89% of the company’s stock.

About Genetic Technologies (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Further Reading: What does a market perform rating mean?

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.